Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
The heterogeneity and complex nature of Alzheimer's disease (AD) is attributed to several genetic risk factors and molecular culprits. The slow pace and increasing failure rate of conventional drug discovery has led to the exploration of complementary strategies based on repurposing approved drugs to treat AD. Drug repurposing (DR) is a cost-effective, low-risk, and efficient approach for identifying novel therapeutic candidates for AD treatment. Similarly, hybrid drug design through the integration of distinct pharmacophores from known or failed drugs and natural products is an interesting strategy to target the multifactorial nature of AD. In this Perspective, we discuss the potential of DR and highlight promising drug candidates that can be advanced for clinical trials, backed by a detailed discussion on their plausible mechanisms of action. Our article fosters research on the hidden potential of DR and hybrid drug design with the goal of unravelling new drugs and targets to tackle AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pioglitazone (30) is a PPARγ agonist widely used in the treatment of T2D.478”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [478]
Citations
Cites
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,635
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Demuro, A., Mina, E., Kayed, R., Milton, S. C., Parker, I., & Glabe, C. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500997200 · Cited by 1,041
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Bomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J.-C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 832
Yoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K., Ohmori, S., Nomiyama, K., Kawano, H., Ueda, K., et al. (1995) · Neurology · doi:10.1212/wnl.45.6.1161 · Cited by 829
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., & Holtzman, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407963200 · Cited by 474
Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study
Driver, J. A., Beiser, A., Au, R., Kreger, B. E., Splansky, G. L., Kurth, T., Kiel, D. P., Lu, K. P., Seshadri, S., & Wolf, P. A. (2012) · BMJ · doi:10.1136/bmj.e1442 · Cited by 425
Dandona, P., Dhindsa, S., Ghanim, H., & Chaudhuri, A. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002101 · Cited by 386
Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling
Kickstein, E., Krauss, S., Thornhill, P., Rutschow, D., Zeller, R., Sharkey, J., Williamson, R., Fuchs, M., Köhler, A., Glossmann, H., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912793107 · Cited by 380
Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Evert, B. O., Dumitrescu-Ozimek, L., Thal, D. R., Landreth, G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503839103 · Cited by 373
Hsu, C.-C., Wahlqvist, M. L., Lee, M.-S., & Tsai, H.-N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101524 · Cited by 372
El-Sappagh, S., Alonso, J. M., Islam, S. M. R., Sultan, A. M., & Kwak, K. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82098-3 · Cited by 363
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo
Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhänel, M., Spruß, T., Bernhardt, G., Graeff, C., Färber, L., Gschaidmeier, H., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15451 · Cited by 359
Tzeng, N.-S., Chung, C.-H., Lin, F.-H., Chiang, C.-P., Yeh, C.-B., Huang, S.-Y., Lu, R.-B., Chang, H.-A., Kao, Y.-C., Yeh, H.-W., et al. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0611-x · Cited by 356
Entry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 355
Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., Humala, N., Seror, I., Bartholomew, S., Rosendorff, C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31547 · Cited by 335
Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study
Schrijvers, E. M. C., Witteman, J. C. M., Sijbrands, E. J. G., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4f6 · Cited by 328
Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease
He, G., Luo, W., Li, P., Remmers, C., Netzer, W. J., Hendrick, J., Bettayeb, K., Flajolet, M., Gorelick, F., Wennogle, L. P., et al. (2010) · Nature · doi:10.1038/nature09325 · Cited by 326
Neff, R. A., Wang, M., Vatansever, S., Guo, L., Ming, C., Wang, Q., Wang, E., Horgusluoglu-Moloch, E., Song, W.-M., Li, A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb5398 · Cited by 324
Brunden, K. R., Zhang, B., Carroll, J., Yao, Y., Potuzak, J. S., Hogan, A.-M. L., Iba, M., James, M. J., Xie, S. X., Ballatore, C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3059-10.2010 · Cited by 320
Ueda, K., Shinohara, S., Yagami, T., Asakura, K., & Kawasaki, K. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010265.x · Cited by 319
Retinoid X receptors: common heterodimerization partners with distinct functions
Lefebvre, P., Benomar, Y., & Staels, B. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.009 · Cited by 309
Gupta, A., Bisht, B., & Dey, C. S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.033 · Cited by 302
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 301
Machine learning identifies candidates for drug repurposing in Alzheimer’s disease
Rodriguez, S., Hug, C., Todorov, P., Moret, N., Boswell, S. A., Evans, K., Zhou, G., Johnson, N. T., Hyman, B. T., Sorger, P. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21330-0 · Cited by 299
O' Neill, C. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.02.025 · Cited by 290
Choi, Y., Kim, H.-S., Shin, K. Y., Kim, E.-M., Kim, M., Kim, H.-S., Park, C. H., Jeong, Y. H., Yoo, J., Lee, J.-P., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301377 · Cited by 289
Lane, C. A., Barnes, J., Nicholas, J. M., Sudre, C. H., Cash, D. M., Parker, T. D., Malone, I. B., Lu, K., James, S.-N., Keshavan, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30228-5 · Cited by 247
Rajasekhar, K., Chakrabarti, M., & Govindaraju, T. (2015) · Chemical Communications · doi:10.1039/c5cc05264e · Cited by 241
Self-citationUp‐regulation of the α‐secretase ADAM10 by retinoic acid receptors and acitretin
Tippmann, F., Hundt, J., Schneider, A., Endres, K., & Fahrenholz, F. (2009) · The FASEB Journal · doi:10.1096/fj.08-121392 · Cited by 224
Artificial intelligence, machine learning, and drug repurposing in cancer
Tanoli, Z., Vähä-Koskela, M., & Aittokallio, T. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1883585 · Cited by 222
Femminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 213
Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210
Habchi, J., Arosio, P., Perni, M., Costa, A. R., Yagi-Utsumi, M., Joshi, P., Chia, S., Cohen, S. I. A., Müller, M. B. D., Linse, S., et al. (2016) · Science Advances · doi:10.1126/sciadv.1501244 · Cited by 208
Tweedie, D., Ferguson, R. A., Fishman, K., Frankola, K. A., Van Praag, H., Holloway, H. W., Luo, W., Li, Y., Caracciolo, L., Russo, I., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-106 · Cited by 204
Drug repositioning and repurposing for Alzheimer disease
Ballard, C., Aarsland, D., Cummings, J., O’Brien, J., Mills, R., Molinuevo, J. L., Fladby, T., Williams, G., Doherty, P., Corbett, A., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0397-4 · Cited by 201
Fan, R., Xu, F., Previti, M. L., Davis, J., Grande, A. M., Robinson, J. K., & Van Nostrand, W. E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4371-06.2007 · Cited by 196
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002660 · Cited by 193
Tsukuda, K., Mogi, M., Iwanami, J., Min, L.-J., Sakata, A., Jing, F., Iwai, M., & Horiuchi, M. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.136879 · Cited by 191
Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases
Husseman, J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00221-9 · Cited by 187
A Common Biological Mechanism in Cancer and Alzheimers Disease?
Behrens, M., Lendon, C., & Roe, C. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486608 · Cited by 184
Perry, T., Holloway, H. W., Weerasuriya, A., Mouton, P. R., Duffy, K., Mattison, J. A., & Greig, N. H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.028 · Cited by 182
Reducing the Risk of Dementia: Efficacy of Long-Term Treatment of Hypertension
Peila, R., White, L. R., Masaki, K., Petrovitch, H., & Launer, L. J. (2006) · Stroke · doi:10.1161/01.str.0000217653.01615.93 · Cited by 181
Ismaili, L., Refouvelet, B., Benchekroun, M., Brogi, S., Brindisi, M., Gemma, S., Campiani, G., Filipic, S., Agbaba, D., Esteban, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.003 · Cited by 178
Fantini, J., & Yahi, N. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001602 · Cited by 173
Brain Insulin Signaling and Alzheimer's Disease: Current Evidence and Future Directions
Schiöth, H. B., Craft, S., Brooks, S. J., Frey, W. H., & Benedict, C. (2012) · Molecular Neurobiology · doi:10.1007/s12035-011-8229-6 · Cited by 168
Matlack, K. E. S., Tardiff, D. F., Narayan, P., Hamamichi, S., Caldwell, K. A., Caldwell, G. A., & Lindquist, S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402228111 · Cited by 166
Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17718-y · Cited by 163
Metformin Improves Learning and Memory in the SAMP8 Mouse Model of Alzheimer’s Disease
Farr, S. A., Roesler, E., Niehoff, M. L., Roby, D. A., McKee, A., & Morley, J. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-181240 · Cited by 162
A Pilot Study of Exenatide Actions in Alzheimer’s Disease
Mullins, R. J., Mustapic, M., Chia, C. W., Carlson, O., Gulyani, S., Tran, J., Li, Y., Mattson, M. P., Resnick, S., Egan, J. M., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190913155950 · Cited by 157
Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor α Inhibitory Activity
Corral, L. G., Muller, G. W., Moreira, A. L., Chen, Y., Wu, M., Stirling, D., & Kaplan, G. (1996) · Molecular Medicine · doi:10.1007/bf03401909 · Cited by 155
Nepovimova, E., Uliassi, E., Korabecny, J., Peña-Altamira, L. E., Samez, S., Pesaresi, A., Garcia, G. E., Bartolini, M., Andrisano, V., Bergamini, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010804 · Cited by 151
Vitamin A and Alzheimer's disease
Ono, K., & Yamada, M. (2012) · Geriatrics & Gerontology International · doi:10.1111/j.1447-0594.2011.00786.x · Cited by 151
Cancino, G. I., Toledo, E. M., Leal, N. R., Hernandez, D. E., Yévenes, L. F., Inestrosa, N. C., & Alvarez, A. R. (2008) · Brain · doi:10.1093/brain/awn125 · Cited by 147
Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade
Jacobsen, J. S., Comery, T. A., Martone, R. L., Elokdah, H., Crandall, D. L., Oganesian, A., Aschmies, S., Kirksey, Y., Gonzales, C., Xu, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710823105 · Cited by 146
Duration of antihypertensive drug use and risk of dementia: A prospective cohort study
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Breteler, M. M. B., & Stricker, B. H. C. (2009) · Neurology · doi:10.1212/01.wnl.0000345062.86148.3f · Cited by 140
McClean, P. L., Jalewa, J., & Hölscher, C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.024 · Cited by 135
Kimura, R., Okouchi, M., Fujioka, H., Ichiyanagi, A., Ryuge, F., Mizuno, T., Imaeda, K., Okayama, N., Kamiya, Y., Asai, K., et al. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.05.025 · Cited by 133
Paclitaxel (TAXOL®) concentrations in brain tumor tissue
Heimans, J. J., Vermorken, J. B., Wolbers, J. G., Eeltink, C., Meijer, O. W. M., TAPHOORN, M. J. B., & Beijnen, J. H. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058736 · Cited by 131
Chiang, M., Cheng, Y., Chen, S., Yen, C., & Huang, R. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.08.013 · Cited by 131
Ryu, J. K., Franciosi, S., Sattayaprasert, P., Kim, S. U., & McLarnon, J. G. (2004) · Glia · doi:10.1002/glia.20051 · Cited by 129
Rochais, C., Lecoutey, C., Gaven, F., Giannoni, P., Hamidouche, K., Hedou, D., Dubost, E., Genest, D., Yahiaoui, S., Freret, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00115 · Cited by 129
Metal imaging in neurodegenerative diseases
Bourassa, M. W., & Miller, L. M. (2012) · Metallomics · doi:10.1039/c2mt20052j · Cited by 121
Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease
Jerábek, J., Uliassi, E., Guidotti, L., Korábečný, J., Soukup, O., Šepsová, V., Hrabinová, M., Kuča, K., Bartolini, M., Peña‐Altamira, E., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.048 · Cited by 117
c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice
Cancino, G. I., Perez de Arce, K., Castro, P. U., Toledo, E. M., von Bernhardi, R., & Alvarez, A. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.007 · Cited by 110
Metformin Treatment Alters Memory Function in a Mouse Model of Alzheimer's Disease
DiTacchio, K. A., Heinemann, S. F., & Dziewczapolski, G. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141332 · Cited by 109
Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells
Tamilarasan, K., Kolluru, G. K., Rajaram, M., Indhumathy, M., Saranya, R., & Chatterjee, S. (2006) · BMC Cell Biology · doi:10.1186/1471-2121-7-17 · Cited by 108
Role of genes linked to sporadic Alzheimer’s disease risk in the production of β-amyloid peptides
Bali, J., Gheinani, A. H., Zurbriggen, S., & Rajendran, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201632109 · Cited by 107
Hölscher, C., & Li, L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.023 · Cited by 100
Antioxidant Berberine-Derivative Inhibits Multifaceted Amyloid Toxicity
Rajasekhar, K., Samanta, S., Bagoband, V., Murugan, N. A., & Govindaraju, T. (2020) · iScience · doi:10.1016/j.isci.2020.101005 · Cited by 99
Self-citationLi, L., Zhang, Z., Hölscher, C., Gao, C., Jiang, Y., & Liu, Y. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.005 · Cited by 98
Abramov, A. Y., Ionov, M., Pavlov, E., & Duchen, M. R. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00685.x · Cited by 96
Rationally Designed Peptidomimetic Modulators of Aβ Toxicity in Alzheimer's Disease
Rajasekhar, K., Suresh, S. N., Manjithaya, R., & Govindaraju, T. (2015) · Scientific Reports · doi:10.1038/srep08139 · Cited by 95
Self-citationBis(7)‐tacrine attenuates β amyloid‐induced neuronal apoptosis by regulating L‐type calcium channels
Fu, H., Li, W., Lao, Y., Luo, J., Lee, N. T. K., Kan, K. K. W., Tsang, H. W., Tsim, K. W. K., Pang, Y., Li, Z., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03960.x · Cited by 95
Seok, H., Lee, M., Shin, E., Yun, M. R., Lee, Y., Moon, J. H., Kim, E., Lee, P. H., Lee, B., Kang, E. S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40736-x · Cited by 95
A New Face for Old Antibiotics: Tetracyclines in Treatment of Amyloidoses
Stoilova, T., Colombo, L., Forloni, G., Tagliavini, F., & Salmona, M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400161p · Cited by 93
López-Iglesias, B., Pérez, C., Morales-García, J. A., Alonso-Gil, S., Pérez-Castillo, A., Romero, A., López, M. G., Villarroya, M., Conde, S., & Rodríguez-Franco, M. I. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5000613 · Cited by 89
Xu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., & Hu, S. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000129 · Cited by 89
Viral Involvement in Alzheimer’s Disease
Sait, A., Angeli, C., Doig, A. J., & Day, P. J. R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00719 · Cited by 85
Candesartan ameliorates brain inflammation associated with Alzheimer's disease
Torika, N., Asraf, K., Apte, R. N., & Fleisher‐Berkovich, S. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12802 · Cited by 82
Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models
Balducci, C., Santamaria, G., La Vitola, P., Brandi, E., Grandi, F., Viscomi, A. R., Beeg, M., Gobbi, M., Salmona, M., Ottonello, S., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.002 · Cited by 81
Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
Balducci, C., & Forloni, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00738 · Cited by 76
Identification of Antihypertensive Drugs Which Inhibit Amyloid-β Protein Oligomerization
Zhao, W., Wang, J., Ho, L., Ono, K., Teplow, D. B., & Pasinetti, G. M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0925 · Cited by 75
Tsuji, S., Hase, T., Yachie-Kinoshita, A., Nishino, T., Ghosh, S., Kikuchi, M., Shimokawa, K., Aburatani, H., Kitano, H., & Tanaka, H. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00826-3 · Cited by 75
He, P., Cheng, X., Staufenbiel, M., Li, R., & Shen, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055091 · Cited by 73
Li, G., Faibushevich, A., Turunen, B. J., Yoon, S. O., Georg, G., Michaelis, M. L., & Dobrowsky, R. T. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01526.x · Cited by 71
Bolognesi, M. L., Cavalli, A., Bergamini, C., Fato, R., Lenaz, G., Rosini, M., Bartolini, M., Andrisano, V., & Melchiorre, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901123n · Cited by 70
Bexarotene Blocks Calcium-Permeable Ion Channels Formed by Neurotoxic Alzheimer’s β-Amyloid Peptides
Fantini, J., Di Scala, C., Yahi, N., Troadec, J.-D., Sadelli, K., Chahinian, H., & Garmy, N. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn400183w · Cited by 69
Hybrid Multifunctional Modulators Inhibit Multifaceted Aβ Toxicity and Prevent Mitochondrial Damage
Rajasekhar, K., Mehta, K., & Govindaraju, T. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00033 · Cited by 69
Self-citationWilliams, G., Gatt, A., Clarke, E., Corcoran, J., Doherty, P., Chambers, D., & Ballard, C. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0555-x · Cited by 69
Fancellu, G., Chand, K., Tomás, D., Orlandini, E., Piemontese, L., Silva, D. F., Cardoso, S. M., Chaves, S., & Santos, M. A. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1689237 · Cited by 69
Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer’s Disease
Calvo-Rodríguez, M., Kharitonova, E. K., & Bacskai, B. J. (2020) · Cells · doi:10.3390/cells9112513 · Cited by 68
Kehoe, P. G., & Passmore, P. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111376 · Cited by 67
Moorthy, H., & Govindaraju, T. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01319 · Cited by 64
Self-citationEFFECTS OF NIMODIPINE ON CEREBRAL BLOOD FLOW AND NEUROPSYCHOLOGICAL OUTCOME AFTER CARDIAC SURGERY
Forsman, M., Olsnes, B. T., Semb, G., & Steen, P. A. (1990) · British Journal of Anaesthesia · doi:10.1093/bja/65.4.514 · Cited by 63
Samanta, S., Rajasekhar, K., Babagond, V., & Govindaraju, T. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00216 · Cited by 59
Self-citationWeintraub, M. K., Bisson, C. M., Nouri, J. N., Vinson, B. T., Eimerbrink, M. J., Kranjac, D., Boehm, G. W., & Chumley, M. J. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2013.05.002 · Cited by 57
Antihypertensive agents in Alzheimer’s disease: beyond vascular protection
Lebouvier, T., Chen, Y., Duriez, P., Pasquier, F., & Bordet, R. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1708195 · Cited by 55
Injectable Silk Fibroin-Based Hydrogel for Sustained Insulin Delivery in Diabetic Rats
Maity, B., Samanta, S., Sarkar, S., Alam, S., & Govindaraju, T. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00152 · Cited by 53
Self-citationPenazzi, L., Tackenberg, C., Ghori, A., Golovyashkina, N., Niewidok, B., Selle, K., Ballatore, C., Smith, A. B., Bakota, L., & Brandt, R. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.002 · Cited by 51
Bellozi, P. M. Q., Lima, I. V. D. A., Doria, J. G., Vieira, É. L. M., Campos, A. C., Candelario‐Jalil, E., Reis, H. J., Teixeira, A. L., Ribeiro, F. M., & de Oliveira, A. C. P. (2016) · Scientific Reports · doi:10.1038/srep25226 · Cited by 51
Blanco-Silvente, L., Capellà, D., Garre-Olmo, J., Vilalta-Franch, J., & Castells, X. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0857-5 · Cited by 51
Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
Bittar, A., Sengupta, U., & Kayed, R. (2018) · npj Vaccines · doi:10.1038/s41541-018-0046-8 · Cited by 50
Chaves, S., Piemontese, L., Hiremathad, A., & Santos, M. A. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170330092304 · Cited by 48
Hussain, I., Fabrègue, J., Anderes, L., Ousson, S., Borlat, F., Eligert, V., Berger, S., Dimitrov, M., Alattia, J.-R., Fraering, P. C., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.370924 · Cited by 45
SPIEDw: a searchable platform-independent expression database web tool
Williams, G. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-765 · Cited by 44
Kawahara, K., Nishi, K., Suenobu, M., Ohtsuka, H., Maeda, A., Nagatomo, K., Kuniyasu, A., Staufenbiel, M., Nakagomi, M., Shudo, K., et al. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.1307 · Cited by 38
Jia, X.-T., Ye-Tian, Yuanli, Zhang, G., Liu, Z., Di, Z., Ying, X., Yan, F., Song, E., Qi, J., et al. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.03.016 · Cited by 38
Estrada, L. D., Chamorro, D., Yañez, M. J., González, M., Leal, N. R., Rommy von Bernhardi, M., Dulcey, A. E., Marugán, J., Ferrer, M., Soto, C. A., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151087 · Cited by 38
Hanyu, H., Hirao, K., Shimizu, S., Iwamoto, T., Koizumi, K., & Abe, K. (2007) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32804c58aa · Cited by 37
The Continuing Failure of Bexarotene in Alzheimer’s Disease Mice
Balducci, C., Paladini, A., Micotti, E., Tolomeo, D., La Vitola, P., Grigoli, E., Richardson, J. C., & Forloni, G. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150029 · Cited by 37
Tweedie, D., Frankola, K. A., Luo, W., Li, Y., & Greig, N. H. (2011) · The Open Biochemistry Journal · doi:10.2174/1874091x01105010037 · Cited by 34
Jojo, G. M., & Kuppusamy, G. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12808 · Cited by 34
Association between exenatide use and incidence of Alzheimer's disease
Zhou, B., Zissimopoulos, J., Nadeem, H., Crane, M. A., Goldman, D. P., & Romley, J. A. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12139 · Cited by 33
Wang, X., Wang, L., Xu, Y., Yu, Q., Li, L., & Guo, Y. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0548-z · Cited by 31
Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer’s Disease
Górecki, L., Uliassi, E., Bartolini, M., Janočková, J., Hrabinová, M., Hepnarová, V., Prchal, L., Múčková, Ľ., Pejchal, J., Karasová, J. Ž., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00184 · Cited by 31
A Systematic SAR Study of C10 Modified Paclitaxel Analogues Using a Combinatorial Approach
Liu, Y., Ali, S. M., Boge, T. C., Georg, G. I., Victory, S. F., Zygmunt, J., Marquez, R. T., & Himes, R. H. (2002) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207023330615 · Cited by 29
The Retinoic Acid Receptor Agonist Am80 Increases Hippocampal ADAM10 in Aged SAMP8 Mice
Kitaoka, K., Shimizu, N., Ono, K., Chikahisa, S., Nakagomi, M., Shudo, K., Ishimura, K., Séi, H., & Yoshizaki, K. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.009 · Cited by 27
Desai, R. J., Varma, V. R., Gerhard, T., Segal, J., Mahesri, M., Chin, K., Nonnenmacher, E., Gabbeta, A., Mammen, A. M., Varma, S., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12095 · Cited by 27
NVP-BEZ235 (Dactolisib) Has Protective Effects in a Transgenic Mouse Model of Alzheimer’s Disease
Bellozi, P. M. Q., Gomes, G. F., de Oliveira, L. R., Olmo, I. G., Vieira, É. L. M., Ribeiro, F. M., Fiebich, B. L., & de Oliveira, A. C. P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01345 · Cited by 25
Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer’s disease
Ballard, C. G., Corbett, A., & Sharp, S. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.13 · Cited by 22
Guarnieri, G., Sarchielli, E., Gallina, P., & Morelli, A. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162732 · Cited by 21
CANCER LINKED TO ALZHEIMER DISEASE BUT NOT VASCULAR DEMENTIA
Kinnunen, P. K. J. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f001fb · Cited by 20
Cell–Cell Signaling: The ins and outs of receptor tyrosine phosphatases
Fashena, S. J., & Zinn, K. (1995) · Current Biology · doi:10.1016/s0960-9822(95)00272-7 · Cited by 17
Ballard, C. G., Creese, B., Gatt, A. P., Doherty, P., Francis, P. T., Whitfield, D., Corbett, A., Corcoran, J., Hanger, D. P., Thuret, S., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/622308 · Cited by 7
Hureau, C. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162732-00170 · Cited by 7
Balmik, A. A., Das, R. R., Sonawane, S. K., & Chinnathambi, S. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162732-00137 · Cited by 7
Chapter 11 – Microtubule Stabilization
Ballatore, C., Smith, A. B., Lee, V., Trojanowski, J., & Brunden, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00011-3 · Cited by 1
Chapter 9. Post-translational Modifications and Alzheimer's Disease
Padhi, D., Ramesh, M., & Govindaraju, T. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162732-00255 · Cited by 1
Self-citationMishra, A., Ramesh, M., & Govindaraju, T. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162732-00329 · Cited by 1
Self-citation
Research works printed but not linked: 5
- Samanta S., 2022, Alzheimer’s Disease: Recent Findings in Pathophysiology, Diagnostic and Therapeutic Modalities, 1
- 10.1039/c5cc05264e · DOI · Paper page
- 10.1021/acschemneuro.8b00033 · DOI · Paper page
- 10.1172/jci0215451 · doi:10.1172/jci0215451 · Paper page
- Wang S., 2016, J. Alzheimers Parkinsonism Dement., 1, 007
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Yan, C., Dai, J., Yao, Y., Fu, W., Tian, H., Zhu, W., & Guo, Z. (2023) · Nature Protocols · doi:10.1038/s41596-022-00789-1 · Cited by 106
Multipronged diagnostic and therapeutic strategies for Alzheimer's disease
Ramesh, M., & Govindaraju, T. (2022) · Chemical Science · doi:10.1039/d2sc03932j · Cited by 94
Self-citationPadhi, D., Baruah, P., Ramesh, M., Moorthy, H., & Govindaraju, T. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103119 · Cited by 48
“We rationally designed and synthesized hybrid molecules by strategically integrating the structural and functional features of GA and CDPs to enhance their multifunctional therapeutic properties [34].”
MethodSelf-citationShoukat, S., Zia, M. A., Uzair, M., Attia, K. A., Abushady, A. M., Fiaz, S., Ali, S., Yang, S. H., & Ali, G. M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21161 · Cited by 39
“Therefore, developing more potent and effective medicinal chemicals is necessary [12].”
Background
Metadata
- Authors
- Padhi, D., & Govindaraju, T.
- Affiliations
- Jawaharlal Nehru Centre for Advanced Scientific Research (IN)
- Corresponding author
- Govindaraju, Thimmaiah
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-05-13
- Volume
- 65
- Issue
- 10
- Pages
- 7088-7105
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4280528552
- Cited by
- 47
- References
- 143
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 17 · 2023: 13 · 2022: 3
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Science and Engineering Research Board (CRG/2020/004594)
- Department of Science and Technology, Ministry of Science and Technology (DST/SJF/CSA-02/2015-2016, IFCPAR/CEFIPRA-62T10-3)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- Alzheimer's disease, drug repurposing, hybrid drug design, mechanism of action, natural products, complex diseases, clinical trial candidates
- MeSH terms
- Alzheimer Disease, Humans, Drug Discovery, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.